Inhibitory effect of dibenzofuran and dibenzosuberol derivatives on rhinovirus replication in vitro; effective prevention of viral entry by dibenzosuberenone

Antiviral Research

Volumn 44, Issue 2, 1999, Pages 123-131

  Murray, M A ^a   Babe, L M ^a  

^a Axys Pharmaceuticals Inc   (United States)

Author keywords

Antiviral; Dibenzofuran; Dibenzosuberenone; Dibenzosuberol; Rhinovirus; Virus entry; Virus replication

Indexed keywords

CAPSID PROTEIN; DIBENZOFURAN; DIBENZOFURAN DERIVATIVE; DIBENZOSUBERENONE; DIBENZOSUBEROL; UNCLASSIFIED DRUG; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; HELA CELL; HUMAN; HUMAN CELL; HUMAN RHINOVIRUS; PRIORITY JOURNAL; VIRUS ADSORPTION; VIRUS CAPSID; VIRUS CELL INTERACTION; VIRUS INHIBITION; VIRUS PARTICLE; VIRUS REPLICATION;

ANTIVIRAL AGENTS; BENZENE DERIVATIVES; BENZOFURANS; BLOTTING, WESTERN; CYTOPATHOGENIC EFFECT, VIRAL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HELA CELLS; HUMANS; PLAQUE ASSAY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHINOVIRUS; VIRUS REPLICATION;

HUMAN RHINOVIRUS SP.; MIRIDAE; RHINOVIRUS;

EID: 0032761324     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(99)00061-3     Document Type: Article

References (27)

1. Albrecht W.L., Fleming R.W., Horgan S.W., Mayer G.D. Bis-basic substituted polycyclic aromatic compounds. A new class of antiviral agents. 8. Bis-basic derivatives of carbazole, dibenzofuran, and dibenzothiophene. J. Med. Chem. 20:1977;364-371.
2. Andries K., Dewindt B., De Brabander M., Stokbroek R., Janssen P.A. In vitro activity or R 61837, a new antirhinovirus compound. Arch. Virol. 101:1988;155-167.
3. Arruda E., Hayden F.G. Update on therapy of influenza and rhinovirus infections. Adv. Exp. Med. Biol. 394:1996;175-187.
4. Barrow G.I., Higgins P.G., Tyrrell D.A., Andries K. An appraisal of the efficacy of the antiviral R 61837 in rhinovirus infections in human volunteers. Antivir. Chem. Chemother. 1:1990;279-283.
5. Carrasco L. Picornavirus inhibitors. Pharm. Ther. 64:1994;215-290.
6. Diana G.D., Nitz T.J., Mallamo J.P., Treasurywalla A. Antipicornavirus compounds: use of rational drug design and molecular modelling. Antivir. Chem. Chemother. 4:1993;1-10.
7. Dick E.J., Chesney P.J. Rhinoviruses. Chesney P.J. Textbook of Pediatric Infectious Disesase. 1981;1167-1186 W.B. Saunders Co, Philadelphia, PA.
8. Gwaltney J.M. Rhinoviruses. Evans A.S. Viral Infections of Humans: Epidemiology and Control. 2nd ed. 1992;491-517 Plenum Publishing, New York.
9. Gwaltney J.M. Rhinovirus infection of the normal human airway. Am. J. Respir. Crit. Care Med. 152:1995;S36-S39.
10. Hayden F.G., Hipskind G.J., Woerner D.H., Eisen G.F., Janssens M., Janssen P.A., Andries K. Intranasal pirodavir (R77,975) treatment of rhinovirus colds. Antimicrob. Agents Chemother. 39:1995;290-294.
11. Johnston S., Pattemore P., Sandeson G., Smith S., Campbell M., Josephs L., Cunningham A., Robinson B., Myint S., Ward M., Tyrrell D., Holgate S. The relationship between upper respiratory infections and hospital admissions for asthma: a time-trend analysis. Am. J. Respir. Crit. Care Med. 154:1996;654-660.
12. Kenny M.Y., Dulworth J.K., Torney H.L. In vitro and in vivo antipicornavirus activity of some phenoxypyridinecarbonitriles. Antimicrob. Agents Chemother. 28:1985;745-750.
13. McKinlay M.A. WIN 51711, a new systematically active broad spectrum antipicornavirus agent. J. Antimicrob. Chemother. 16:1985;284-286.
14. Merluzzi V.J., Cipriano D., McNeil D., Fuchs V., Supeau C., Rosenthal A.S., Skiles J.W. Evaluation of zinc complexes on the replication of rhinovirus 2 in vitro. Res. Commun. Chem. Pathol. Pharmacol. 66:1989;425-440.
15. Pattemore P., Johnston S., Bardin P. Viruses as precipitants of asthma symptoms. I. Epidemiology. Clin. Exp. Allergy. 22:1992;325-336.
16. Pevear D.C., Fancher M.J., Felock P.J., Rossmann M.G., Miller M.S., Diana G., Treasurywala A.M., McKinlay M.A., Dutko F.J. Conformational change in the floor of the human rhinovirus canyon blocks adsorption to HeLa cell receptors. J. Virol. 63:1989;2002-2007.
17. Rosenwirth B., Oren D.A., Arnold E., Kis Z.L., Eggers H.J. SDZ 35-682, a new picornavirus capsid binding agent with potent antiviral activity. Antivir. Res. 26:1995;65-82.
18. Rossmann M.G. Antiviral agents targeted to interact with viral capsid proteins and possible applications to human immunodeficiency virus. Proc. Natl. Acad. Sci. USA. 85:1988;4625-4627.
19. Rueckert R.R. Picornaviridae: the viruses and their replication. Fields B. 3rd edition Virology. 1:1996;609-654 Lippincott-Raven Publishers, Philadelphia, PA.
20. Sherry B., Rueckert R.R. Evidence for at least two dominant neutralization antigens on human rhinovirus 14. J. Virol. 53:1985;137-143.
21. Smerberck, R.V., Pittz, E.P., 1986. Dibenzosuberone as a non-steroidal anti-inflammatory compound and compositions thereof. Warner-Lambert Company, U.S. (patent).
22. Smith T.J., Kremer M.J., Luo M., Vriend G., Arnold E., Kamer G., Rossmann M.G., McKinlay M.A., Diana G.D., Otto M.J. The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating. Science. 233:1986;1286-1293.
23. Staunton D., Merluzzi V., Rothlein R., Barton R., Marin S., Springer T. A cell adhesion molecule, ICAM-1, is the major surface receptor for rhinoviruses. Cell. 56:1989;849-853.
24. Subauste M.C., Jacoby D.B., Richards S.M., Proud D. Infection of a human respiratory epithelial cell line with rhinovirus. Induction of cytokine release and modulation of susceptibility to infection by cytokine exposure. J. Clin. Invest. 96:1995;549-557.
25. Summers, J.B., Moore, J.L., 1988. Dibenzofuran lipoxygenase inhibiting compounds, composition and use. Abbott Laboratories, U.S. (patent).
26. Tisdale M., Selway J.W. Inhibition of an early stage of rhinovirus replication by dichloroflavan (BW683C). J. Gen. Virol. 64:1983;795-803.
27. Wang W., Lee W.-M., Mosser A.G., Rueckert R.R. WIN 52035 dependent human rhinovirus 16: assembly deficiency caused by mutations near the canyon surface. J. Virol. 72:1998;1210-1218.